We are live on ! Find out more
INFI

Infinity Pharmaceuticals, Inc.

Delisted

INFI was delisted on the 13th of September, 2023.

115 hedge funds and large institutions have $2.76B invested in Infinity Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 41 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

131% more call options, than puts

Call options by funds: $3.19M | Put options by funds: $1.38M

77% more capital invested

Capital invested by funds: $1.56B → $2.76B (+$1.2B)

11% less funds holding

Funds holding: 129115 (-14)

17% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 41

47% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 30

Holders
115
Holders Change
-14
Holders Change %
-10.85%
% of All Funds
3.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
16
Increased
34
Reduced
41
Closed
30
Calls
$3.19M
Puts
$1.38M
Net Calls
+$1.81M
Net Calls Change
-$681K
Name Holding Trade Value Shares
Change
Change in
Stake
PAM
26
Panagora Asset Management
Massachusetts
$3.25M +$702K +81,592 +25%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$2.75M +$856K +99,399 +40%
IGIM
28
I.G. Investment Management
Manitoba, Canada
$2.43M -$199K -23,105 -7%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$2.39M -$513K -59,621 -16%
William Blair & Company
30
William Blair & Company
Illinois
$1.95M +$1.82M +211,936 +576%
EAM
31
Eventide Asset Management
Massachusetts
$1.94M +$427K +49,600 +25%
TCIM
32
TIAA CREF Investment Management
New York
$1.94M -$970K -112,690 -31%
CS
33
Candriam SCA
Luxembourg
$1.89M
CS
34
Credit Suisse
Switzerland
$1.74M -$248K -28,811 -12%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$1.71M -$174K -20,206 -8%
RCAMU
36
Rothschild & Co Asset Management US
Connecticut
$1.7M +$320K +37,145 +21%
RSCM
37
Rock Springs Capital Management
Maryland
$1.69M
Point72 Asset Management
38
Point72 Asset Management
Connecticut
$1.5M +$1.65M +191,400 New
QI
39
QS Investors
New York
$1.43M
BIM
40
Bogle Investment Management
Massachusetts
$1.42M -$2.48M -288,436 -61%
BIM
41
BlackRock Investment Management
Delaware
$1.37M +$11.5K +1,335 +0.8%
BAMS
42
Bellevue Asset Management (Switzerland)
Switzerland
$1.26M +$258K +30,000 +23%
Renaissance Technologies
43
Renaissance Technologies
New York
$1.24M -$6.19M -719,400 -82%
Charles Schwab
44
Charles Schwab
California
$1.18M -$3.88M -450,432 -75%
PIM
45
Platinum Investment Management
Australia
$1.15M +$336K +39,000 +36%
MIG
46
Mariner Investment Group
New York
$1.08M
VRS
47
Virginia Retirement Systems
Virginia
$1.06M +$87.8K +10,200 +8%
GC
48
Globeflex Capital
California
$1.05M -$107K -12,374 -8%
UBS Group
49
UBS Group
Switzerland
$1.03M +$1.11M +128,639 +5,305%
RCMC
50
Rubric Capital Management (Connecticut)
Connecticut
$981K +$1.08M +125,000 New

INFI Hedge Fund Activity: Q4 2015 in Review

115 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q4 2015, worth a combined $2.76B — up 77% from $1.56B a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of INFI and 16 opened new positions — a net loss of 14 holders — while 41 trimmed existing stakes and 34 added.

The largest buyer was Millennium Management, adding an estimated $11M. The largest seller was Goldman Sachs, cutting an estimated $21.2M.

  • 115 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q4 2015, down from 129 in Q3 2015.
  • Funds reported $2.76B of Infinity Pharmaceuticals, Inc. stock for Q4 2015, up 77% quarter-over-quarter.
  • 16 funds opened new Infinity Pharmaceuticals, Inc. positions in Q4 2015 and 30 closed out, a net change of -14 holders.
  • The largest Infinity Pharmaceuticals, Inc. buyer in Q4 2015 was Millennium Management, an estimated $11M added.
  • The largest Infinity Pharmaceuticals, Inc. seller in Q4 2015 was Goldman Sachs, an estimated $21.2M sold.

Based on aggregated 13F filings for Q4 2015.